Amid the biotechnology sector's transformative era the Direxion Daily Biotech Top 5 Bull 2X ETF ($TBXU) offers traders a new, single-trade solution to gain 2X daily leveraged exposure to an e
− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran’s Differentiated Profile – − Cardiovascular Magnetic Resonance...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: ...
− Generated Q3 2025 Total Net Product Revenues of $851 Million (103% Growth Compared with Q3 2024), Driven Primarily by Total TTR Revenues of $724 Million (135% Growth Compared with Q3 2024) – ...
Leerink Partners analyst Mani Foroohar maintained a Hold rating on Alnylam Pharma yesterday and set a price target of $370.00. The company’s shares closed yesterday at $470.27.Elevate Your Investing...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday,...
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma, with a price target of $570.00. The company’s shares closed yesterday at $456.95.Elevate Your...
In a report released on October 8, Luca Issi from RBC Capital maintained a Buy rating on Alnylam Pharma. The company’s shares closed yesterday at $456.95.Elevate Your Investing Strategy: Take advantage...
Alnylam Pharmaceuticals ((ALNY)), Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...